Switch theme
Sign up to access all valuation multiples
China Resources Sanjiu Medical & Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in the research and development, production and sale of pharmaceutical products, healthcare products, and medical appliances under the brand name 999, which includes OTC, antibiotic and raw material drug. The other brands under which the company offers its products are Lee King, Shunfeng, and Tianhe. The company's core business is located in OTC and Chinese medicine prescription drugs, OTC core products in the cold, gastrointestinal, skin, pediatric, cough and orthopedic drugs occupy a higher market share; prescription drug products in traditional Chinese medicine formula granules, cardiovascular and cerebrovascular, anti-tumor in the field of anti-infection and other areas.
1999
603
LTM Revenue $3.9B
LTM EBITDA $732M
$7.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
China Resources Sanjiu has a last 12-month revenue of $3.9B and a last 12-month EBITDA of $732M.
In the most recent fiscal year, China Resources Sanjiu achieved revenue of $3.8B and an EBITDA of $758M.
China Resources Sanjiu expects next 12-month revenue of XXX and NTM EBITDA of XXX
See China Resources Sanjiu valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $3.4B | $3.8B | XXX | XXX | XXX |
| Gross Profit | $1.3B | $1.8B | XXX | XXX | XXX |
| Gross Margin | 39% | 48% | XXX | XXX | XXX |
| EBITDA | $637M | $758M | XXX | XXX | XXX |
| EBITDA Margin | 19% | 20% | XXX | XXX | XXX |
| Net Profit | $337M | $393M | XXX | XXX | XXX |
| Net Margin | 10% | 10% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, China Resources Sanjiu's stock price is CNY 44 (or $6).
China Resources Sanjiu has current market cap of CNY 56.5B (or $7.8B), and EV of CNY 51.1B (or $7.0B).
See China Resources Sanjiu trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.0B | $7.8B | XXX | XXX | XXX | XXX | $0.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, China Resources Sanjiu has market cap of $7.8B and EV of $7.0B.
China Resources Sanjiu's trades at 1.8x LTM EV/Revenue multiple, and 9.6x LTM EBITDA.
Analysts estimate China Resources Sanjiu's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for China Resources Sanjiu and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $7.0B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 9.3x | XXX | XXX | XXX |
| P/E | 16.8x | XXX | XXX | XXX |
| P/E/Growth | 1.2x | XXX | XXX | XXX |
| EV/FCF | 14.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpChina Resources Sanjiu's NTM/LTM revenue growth is 12%
China Resources Sanjiu's revenue per employee for the last fiscal year averaged $6.3M, while opex per employee averaged $2.2M for the same period.
Over next 12 months, China Resources Sanjiu's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate China Resources Sanjiu's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for China Resources Sanjiu and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 32% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $6.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 35% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
China Resources Sanjiu acquired XXX companies to date.
Last acquisition by China Resources Sanjiu was XXXXXXXX, XXXXX XXXXX XXXXXX . China Resources Sanjiu acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was China Resources Sanjiu founded? | China Resources Sanjiu was founded in 1999. |
| Where is China Resources Sanjiu headquartered? | China Resources Sanjiu is headquartered in China. |
| How many employees does China Resources Sanjiu have? | As of today, China Resources Sanjiu has 603 employees. |
| Is China Resources Sanjiu publicy listed? | Yes, China Resources Sanjiu is a public company listed on SHE. |
| What is the stock symbol of China Resources Sanjiu? | China Resources Sanjiu trades under 000999 ticker. |
| When did China Resources Sanjiu go public? | China Resources Sanjiu went public in 2000. |
| Who are competitors of China Resources Sanjiu? | Similar companies to China Resources Sanjiu include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of China Resources Sanjiu? | China Resources Sanjiu's current market cap is $7.8B |
| What is the current revenue of China Resources Sanjiu? | China Resources Sanjiu's last 12-month revenue is $3.9B. |
| What is the current EBITDA of China Resources Sanjiu? | China Resources Sanjiu's last 12-month EBITDA is $732M. |
| What is the current EV/Revenue multiple of China Resources Sanjiu? | Current revenue multiple of China Resources Sanjiu is 1.8x. |
| What is the current EV/EBITDA multiple of China Resources Sanjiu? | Current EBITDA multiple of China Resources Sanjiu is 9.6x. |
| What is the current revenue growth of China Resources Sanjiu? | China Resources Sanjiu revenue growth between 2023 and 2024 was 12%. |
| Is China Resources Sanjiu profitable? | Yes, China Resources Sanjiu is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
